menu
Human Microbiome-based Products Market is growing at an annualized rate of over 40%.
The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community

Over the years, extensive R&D efforts haveestablished the basis for a wide range of microbiome-based therapeutic anddiagnostic products, which may cause a paradigm shift in the way healthcare isdelivered in the foreseen future

 

Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030”report to its list of offerings.

 

The concept ofmicrobiome-based therapeutics has generated significant enthusiasm within themedical science community, defining a new frontier in the field of medicine.Despite having captured the interest of several venture capital firms and bigpharma players, no microbiome-based therapeutic has been officially approved byan authorized medical product regulator. However, the current developmentpipeline of microbiome therapeutics has several promising candidates that arelikely to result in commercial success stories soon.

 

To order this 640+page report, which features 235+ figures and 275+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

 

Key Market Insights

 

260therapy candidates are currently in different phases of development

Nearly 25% ofpipeline drugs are in the clinical phase of development, while the rest are in thepreclinical / discovery stage. Interestingly, most of these drugs targetdigestive and gastrointestinal disorders (20%); this is followed by productcandidates intended for treatment of oncological disorders (17%) and infectiousdiseases (13%).

 

Over30 microbiome diagnostic tests are currently available / under development

Around30% of the abovementioned tests have been commercialized, while the rest areunder development. Of the total tests, notable examples of companies that launcheda microbiome-based diagnostic solution include (in alphabetical order)ARTPred, Genetic Analysis, Goodgut, Invivo Healthcare, IS-diagnostics, LuxiaScientific and Varinos.

 

FMTsare the only commercially available microbiome therapy

Thistherapeutic product is presently indicated for the treatment of recurrent Clostridiumdifficile infections (rCDIs). Further, non-industry players (such asUniversity of Alberta, The Second Hospital of Nanjing Medical University,University of California and Chinese University of Hong Kong) are makingnotable contributions in this arena, having been involved in ~200 clinicaltrials till August 2019.

 

 

Contractservice providers have become an integral part of the microbiome supply chain

Presently,certain firms claim to offer a wide array of contract research / manufacturingservices for microbiome therapeutics. Examples of such players include AdarePharmaceuticals, Biose, Cobra Biologics, CoreBiome, List BiologicalLaboratories, NIZO, ProDigest, Quay Pharma and Wacker Chemie.

 

NorthAmerica and Europe are anticipated to capture over 85% of the market share by2030

As latestage products are commercialized, the microbiome therapeutics market is likelyto grow at an annualized growth rate of over 30%, during the next decade. Inaddition to North America and Europe, the market in China / broader AsiaPacific region is also anticipated to grow at a relatively faster rate.

 

To request a samplecopy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

 

 

 

The USD 4 billion (by 2030) financial opportunitywithin the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, hasbeen analyzed across the following segments:

§  Typeof Therapy (Tx)

§  PrescriptionDrug

§  Prebiotics

§  Probiotics

 

§  Typeof Molecule (Tx)

§  SmallMolecules

§  Biologics

 

§  TargetIndication (Tx+Dx)

§  AcneVulgaris

§  AtopicDermatitis

§  Clostridiumdifficile Infection

§  ColorectalCancer

§  Crohn’sDisease

§  Diabetes

§  IrritableBowel Syndrome

§  LactoseIntolerance

§  LungCancer

§  Nonalcoholicsteatohepatitis (NASH)

§  Obesity

§  Ulcerativecolitis

 

§  TherapeuticArea (Tx+Dx)

§  AutoimmuneDisorders

§  DentalDisorders

§  Digestiveand Gastrointestinal Disorders

§  DermatologicalDisorders

§  InfectiousDisease

§  MetabolicDisorders

§  Oncology

§  Others

 

§  KeyGeographical Regions (Tx+Dx)

§  NorthAmerica

§  Europe

§  Asia-Pacificand Rest of the World

 

The report featuresinputs from eminent industry stakeholders, according to whom innovation inmicrobiome-related research is mostly being driven by start-ups / small-sizedcompanies. The report includes detailed transcripts of discussions held withthe following experts:

§ Veronika Oudova (Co-founder and Chief Executive Officer,S-Biomedic)

§ Colleen Cutcliffe (Co-founder and Chief Executive Officer,Whole Biome)

§ Lee Jones (President and Chief Executive Officer, Rebiotix)

§ Mark Heiman (Chief Scientific Officer and Vice President,Research, MicroBiome Therapeutics)

§ Assaf Oron (Chief Business Officer, BiomX)

§ Pierre-Alain Bandinelli (Chief Business Officer, DaVolterra)

§ Nikole E Kimes (Co-founder and Vice President, SioltaTherapeutics)

§ James Burges (Executive Director, OpenBiome)

§ JP Benya (Vice President, Business Development, AssemblyBiosciences)

§ Debbie Pinkston (Vice President, Sales and BusinessDevelopment, List Biological Laboratories)

§ Gregory J Kuehn (Vice President, Business Development andMarketing, Metabiomics)

§ Alexander Segal (Vice President, Business Development,Universal Stabilization Technologies)

§ Alexander Lin (Associate General Manager, Chung MeiPharmaceutical)

§ Aaron Wright (Senior Scientist, Pacific Northwest NationalLaboratories)

 

The research coversdetailed profiles, featuring a brief company overview, its financialinformation (if available), productportfolio details (such as status of development of pipeline candidates,clinical trial information and analysis of key trial end-points), recentdevelopments and an informed future outlook.

§  4DPharma

§  ArmataPharmaceuticals

§  EveloBiosciences

§  Rebiotix(Acquired by Ferring Pharmaceuticals)

§  SeresTherapeutics

§  VedantaBiosciences

 

For additionaldetails, please visit 

https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html oremail sales@rootsanalysis.com

 

You may also beinterested in the following titles:

1.    Antibody Drug Conjugates Market (5th Edition), 2019-2030

2.    Gene Therapy Market (3rd Edition), 2019 - 2030

3.    Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4thEdition), 2019 – 2030

4.    Synthetic Lethality-based Drugs and Targets Market,2019-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com

 

Contact Information

RootsAnalysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter- https://twitter.com/RootsAnalysis